Aiolos Bio
AstraZeneca’s Trixeo gets EU approval for asthma maintenance treatment
Trixeo is the first and only triple-combination therapy approved in the EU for patients 12 years and older, independent of exacerbation history
AstraZeneca’s Trixeo recommended by CHMP for approval in EU for asthma
Asthma affects over 360 million people worldwide, including over 40 million people in Europe
GSK announces bepirovirsen’s ‘functional cure’ data to treat chronic hepatitis B
Over 240 million people worldwide live with chronic hepatitis B
GSK signs agreement with Protas to streamline clinical trials
The new three-year agreement builds on an existing two-year relationship
GSK to acquire 35Pharma for $950m including a potential drug for pulmonary hypertension
PH has a five‑year survival rate of only around 50% and affects up to 82 million people worldwide
GSK’s Arexvy RSV vaccine receives expanded EC approval for use in adults
RSV affects approximately 64 million people around the world each year
GSK’s Nucala approved by MHRA for uncontrolled COPD
Symptoms of COPD include breathlessness, persistent cough and frequent chest infections
GSK’s Blenrep approved by FDA for multiple myeloma
Approval supported by positive results from phase 3 trial
Novartis’ ianalumab shows promise in phase 3 Sjögren’s syndrome studies
The systemic autoimmune disease affects approximately 0.6% of the UK’s adult population
GSK and Hengrui enter multi-programme collaboration agreement worth $12bn
The deal includes a PDE3/4 inhibitor in clinical development for COPD
Novartis and Matchpoint enter inflammatory disease partnership worth $1bn
The companies will focus on inflammatory diseases that have been historically difficult to treat
GSK’s Blenrep combinations granted EC approval for relapsed/refractory multiple myeloma
More than 50,000 cases of the blood cancer are diagnosed in Europe each year